Effects Of Marine Lipid Fraction PCSO-524™ Supplementation On Biochemical And Functional Measures Of Muscle Damage And Soreness In Untrained Men
Year: 2014
Type: dissertation
Abstract: Effects of marine lipid fraction PCSO-524™ supplementation on biochemical and functional \nmeasures of muscle damage and soreness in untrained men \nINTRODUCTION: Intensive or unaccustomed eccentric exercise is known to cause \nexercise-induced muscle damage (EIMD) commonly resulting in delayed onset muscle soreness \n(DOMS). EIMD/DOMS can result in decrements in endurance and resistance exercise \nperformance. Although many treatments have been investigated for the prevention and alleviation \nof EIMD/DOMS, success has been limited. PCSO-524™ has been found to attenuate symptoms \nof inflammatory diseases such as arthritis and asthma, and thus may be a viable treatment for \nEIMD/DOMS and may attenuate related exercise performance decrements. \nPURPOSE: The purpose of this study was to examine whether or not PCSO-524™ \nsupplementation could attenuate loss of range of motion, force loss, swelling, perceived pain \nthrough algometry and biochemical markers of inflammation, intracellular muscle proteins and \noxidative stress after eccentric muscle damage. \nMETHODS: Subjects were thirty-two healthy, untrained males aged 18–26 who had \nnot participated in a resistance training program in the past sixty days and did not exercise for \nmore than three times per week for 30 minutes each session. Subjects supplemented for four \nweeks with either PCSO-524™ (400 mg/day) or placebo, after which time participated in a 20- \nminute downhill run (DHR) at -16% grade. Functional measures of DOMS were measured by \nalgometry, midline thigh girth, and maximal voluntary contraction, following supplementation and \n24, 48, 72 and 96 hours following eccentric exercise. Biochemical indicators of muscle damage \nsuch as Creatine Kinase-MM, Myoglobin, Slow skeletal troponin I, Fatty Acid Binding Protein 3, \nInterleukin-6, Tumor Necrosis Factor Alpha, 8-hydroxy-2' -deoxyguanosine (8-OHdG), and \nCardiac Troponin I was measured pre-supplementation, post-supplementation and following DHR \nat 0, 2, 24, 48, 72 and 96 hours. \nRESULTS: PCSO-524™ attenuated maximal voluntary contraction force loss \nsignificantly at 96 hours (F = 8.140 p < .001). PCSO-524™ attenuated loss of range of motion at \n96 hours compared to baseline (F = 8.236 p < .05) for the PCSO-524™ group but did not change 5 \nfor the placebo group. There was no significant change in muscle swelling from baseline as \nmeasured by thigh girth for either PCSO-524™ or placebo. There was no significant change in \nperceived muscle soreness as measured by algometry for either PCSO-524™ or placebo. There \nwas significant attenuation of creatine kinase MM in the blood following EMD immediately (t = \n4.467, p < .001; 95% CI = 63.0 – 169.2), 2 (t = 5.076, p < .001; 95% CI = 76.1 – 178.6), 24 (t = \n12.829, p < .001; 95% CI = 562.5 – 775.6), 48 (t = 11.477, p < .001; 95% CI = 493.2 – 706.7), 72 \n(t =9.118, p < .001; 95% CI = 359.8 – 567.5), and 96 hours (t = 11.935, p < .001; 95% CI = 574.4 \n– 811.6). Significant attenuation of myoglobin occurred 24 (t = 4.334, p < .001; 95% CI = 22.9 – \n63.7), 48 (t = 6.402, p < .001; 95% CI = 67.7 – 131.1), 72 (t = 5.340, p < .001; 95% CI = 119.0 – \n266.3), and 96 hours (t = 3.272, p < .01; 95% CI = 49.0 – 212.3) compared to placebo. \nSignificant attenuation of skeletal muscle troponin I occurred in the PCSO-524™ group compared \nto placebo 2 (t = 2.562, p < .05; 95% CI = 0.9 – 8.0), 24 (t = 3.561, p < .01; 95% CI = 4.4 – 15.4), \n48 (t = 4.095, p < .001; 95% CI = 4.7 – 14.0), 72 (T = 3.222, p < .01; 95% CI = 2.5 – 11.2), and 96 \nhours (T = 2.177, p < .05; 95% CI = 0.3 – 10.4) post EIMD. No significant effect of \nsupplementation status on fatty acid binding protein appearance in the blood (F = .418 p = .523) \npost EMID. Significant attenuation of Interleukin-6 was observed 24 (t = 3.619, p < .01; 95% CI = \n3.7 – 13.3), 48 (t = 3.993, p < .001; 95% CI = 5.8 – 17.8), 72 (t = 3.621, p < .01; 95% CI = 5.0 – \n17.9), and 96 hours (t = 3.076, p < .01; 95% CI = 3.1 – 15.35) post EMID compared to placebo. A \nsignificant effect of time on TNF alpha concentration in the blood (F = 132.012 p < .001) was \nobserved 24 (t = 4.633, p < .001; 95% CI = 11.1 – 28.5), 48 (t = 4.942, p < .001; 95% CI = 10.6 – \n25.7), 72 (t = 4.747, p < .001; 95% CI = 11.3 – 28.5), and 96 hours (t = 6.349, p < .001; 95% CI = \n16.8 – 32.8) post EIMD. No significant effect of time on 8-OHdG concentration in the blood (F = \n1.018 p .419) was observed in either the PCSO-524™ group or placebo after EIMD. No \nsignificant effect of time was observed on cTn1 concentration in the blood (F = .420 p = .889) in \neither PCSO-524™ or placebo after EIMD. \nCONCLUSIONS: Four weeks of PCSO-524™ supplementation does not improve swelling \nas determined by thigh girth; perceived pain by the use of algometry; appearance of Fatty Acid \nBinding Protein, 8-hydroxy-2' -deoxyguanosine (8-OHdG), and Cardiac Troponin I in the blood in 6 \nuntrained males after downhill running compared to placebo. Four weeks of PCSO-524™ \nsupplementation is effective at attenuating maximal voluntary contraction force loss; loss of range \nof motion; and reducing the appearance of creatine kinase-MM; skeletal muscle troponin I; \ninterleukin-6; and Tumor Necrosis Factor- alpha in the blood in untrained males after downhill \nrunning.
Author: David J. Platt
Language: English
Subfield: Physiology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W357029328